Infectious Disease Institute, Kampala, Uganda   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kampala Uganda (2002)

Organization Overview

First Clinical Trial
2010
NCT01228578
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Infectious Disease Institute | Infectious Disease Institute, Kampala, Uganda | Infectious Diseases Institute-Kampala | Infectious Diseases Institute, Uganda | Infectious Diseases Research Collaboration, Uganda

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

AIDS-Related Opportunistic Infections (Phase 3)

Communicable Diseases (Phase 3)

Cryptococcosis (Phase 4)

Fever (Phase 4)

HIV Infections (Phase 3)

Infections (Phase 3)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Meningitis (Phase 4)

Meningitis, Cryptococcal (Phase 4)

Meningitis, Fungal (Phase 3)

Opportunistic Infections (Phase 3)

Tuberculosis (Phase 4)

Yellow Fever (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 31